lapatinib has been researched along with sulforaphane in 2 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (sulforaphane) | Trials (sulforaphane) | Recent Studies (post-2010) (sulforaphane) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 1,754 | 65 | 1,317 |
| Protein | Taxonomy | lapatinib (IC50) | sulforaphane (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 9 | |
| Macrophage migration inhibitory factor | Homo sapiens (human) | 2.2 | |
| Nitric oxide synthase, inducible | Mus musculus (house mouse) | 0.4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Herman-Antosiewicz, A; Kaczyńska, A; Świerczyńska, J | 1 |
| Herman-Antosiewicz, A; Kaczyńska, A | 1 |
2 other study(ies) available for lapatinib and sulforaphane
| Article | Year |
|---|---|
Sensitization of HER2 Positive Breast Cancer Cells to Lapatinib Using Plants-Derived Isothiocyanates.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Isothiocyanates; Lapatinib; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sulfides; Sulfoxides; Thiocyanates; TOR Serine-Threonine Kinases | 2015 |
Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; Female; Humans; Isothiocyanates; Lapatinib; Quinazolines; Receptor, ErbB-2; Signal Transduction; Sulfides; Sulfoxides; Thiocyanates | 2017 |